EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells

Gülşah Altun iD, Özlem Yönem iD

Current Oncology · 2025

DOI: 10.3390/curroncol32110607 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Gülşah Altun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Sivas Numune State Hospital, 58060 Sivas, Türkiye. Hauptthemen laut MEDLINE: Bevacizumab, Sorafenib, Carcinoma, Neuroendocrine, Thyroid Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Medullary thyroid carcinoma is a rare neuroendocrine tumor with limited therapeutic options, as current kinase inhibitors are often associated with significant toxicity and drug resistance. This study aimed to explore novel treatment strategies by testing targeted agents alone and in combination.

Methods

Human medullary thyroid carcinoma TT cells with RET mutations were treated with Sorafenib, Lapatinib, and Bevacizumab. Cell proliferation was monitored in real time using the xCELLigence system, and apoptosis was assessed by flow cytometry.

Results

Sorafenib and Lapatinib each showed strong, dose-dependent cytotoxic effects, with Lapatinib demonstrating the greatest potency. Bevacizumab alone exhibited minimal cytotoxic activity, but when combined with Sorafenib or Lapatinib it significantly enhanced their effects, even at concentrations that were only partially effective individually. The Lapatinib–Bevacizumab combination produced the most potent inhibition of cell viability, comparable to high-dose monotherapy.

Conclusions

These findings suggest that combining kinase inhibitors with Bevacizumab may enhance antitumor activity, allow the use of lower drug doses, and overcome resistance, representing a promising therapeutic strategy for medullary thyroid carcinoma that warrants further investigation in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabSorafenibCarcinoma, NeuroendocrineThyroid NeoplasmsLapatinibAntineoplastic Combined Chemotherapy ProtocolsHumansCell Line, TumorCell ProliferationApoptosisCell SurvivalAntineoplastic Agents

Stichwörter der Autor:innen

BevacizumabLapatinibRET mutationSorafenibcombination therapymedullary thyroid carcinomatargeted therapy

Substanzen

BevacizumabSorafenibLapatinibAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Sivas Numune State Hospital, 58060 Sivas, Türkiye.
  • Department of Gastroenterology, Bodrum Memorial Hospital, 48400 Bodrum, Türkiye.

ORCID-Profile: Gülşah Altun, Özlem Yönem

Zitieren

APA

Altun, G., & Yönem, Ö. (2025). Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells. Current Oncology. https://doi.org/10.3390/curroncol32110607

Vancouver

Altun G, Yönem Ö. Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells. Current Oncology. 2025. doi:10.3390/curroncol32110607

BibTeX
@article{Altun2025,
  author = {Altun, Gülşah and Yönem, Özlem},
  title = {Cytotoxic Effects of Sorafenib, Lapatinib, and Bevacizumab, Alone and in Combination, on Medullary Thyroid Carcinoma Cells},
  journal = {Current Oncology},
  year = {2025},
  doi = {10.3390/curroncol32110607}
}
Kostenlos starten →